Excelya Group SAS

Excelya Group SAS, based in France, operates as a global Contract Research Organization (CRO), providing tailored solutions for the biotechnology, pharmaceutical, and medical device industries. Founded in 2014 and headquartered in Paris, France, Excelya Group SAS specializes in clinical trial management and related solutions for various medical fields. Over time, the company has effectively expanded its operational scope to support clients across diverse therapeutic areas. In November 2025, Excelya Group SAS raised venture funding led by Eurazeo.

Excelya operates as a leading global Contract Research Organization (CRO) offering a comprehensive range of services tailored to the biotechnology, pharmaceutical, and medical device sectors. The company specializes in clinical trial solutions, which encompass full-service capabilities, functional service provision, and resourcing options designed to meet the diverse needs of its clients. Excelya’s expertise spans various therapeutic areas, including oncology, pediatrics, inflammation, immunology, infectious diseases, pain treatment, and late-phase research. Their services are delivered through a collaborative, one-team approach, ensuring that each project is customized to address specific client requirements, supported by over 40 years of collective experience and insights from over 550 clinical studies.

Excelya's client base includes major biotech and pharmaceutical firms seeking to advance healthcare through innovative therapies, with operations extending across 28 countries, serving markets in Europe, North America, and Asia. Excelya generates revenue through a structured service model that includes full-service engagements, functional service partnerships, and resource provision. These transactions occur as business-to-business (B2B) contracts, where clients engage Excelya for tailored clinical trial management and support services. The organization establishes partnerships with pharmaceutical companies and biotech firms, providing them with the necessary expertise to navigate the complexities of clinical research.

Revenue is driven by the delivery of various services, from regulatory affairs and clinical operations to biostatistics and medical writing. The pricing structure for these services is aligned with the specific requirements of each project, reflecting the comprehensive nature of the support offered. Excelya’s commitment to quality and flexibility in service provision underpins its revenue generation strategy, ensuring strong relationships with clients in the healthcare sector. In November 2025, Excelya Group SAS raised an undisclosed amount of venture funding led by new investor Eurazeo.

The company will use the funding to support its growth initiatives. Plans include launching new products and expanding into additional markets, particularly targeting regions where it currently has minimal presence. The specific release dates for new product offerings will be announced in line with development timelines.